{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:44:35Z","timestamp":1773398675507,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Little is known about the incidence of clinical events and treatment patterns among older adults with dementia-related psychosis. Given that dementia-related psychosis comprises various dementia types, this study describes the incidence of clinical events and treatment patterns by dementia type after patients with dementia are diagnosed with psychosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Adults aged\u2009\u2265\u200965\u00a0years with dementia and newly diagnosed with psychosis were identified in US Medicare claims during 2013\u20132018. Baseline characteristics were evaluated at the time of the psychosis diagnosis. After the initial psychosis diagnosis, incidence rates (IRs) of clinical events (e.g., falls\/fractures, infections, healthcare utilization), mortality, and patterns of antipsychotic treatment were described for each dementia type (Alzheimer\u2019s disease [AD], Parkinson\u2019s disease dementia [PDD], dementia with Lewy bodies [DLB], frontotemporal dementia [FTD], vascular dementia [VD], and unspecified dementia). Daily mean cumulative counts were estimated to describe the incidence of recurrent events over time. Mortality was described using Kaplan\u2013Meier survival curves.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 484,520 patients with dementia-related psychosis: mean age, 84\u00a0years (standard deviation, 7.8); female, 66%. At the time of psychosis diagnosis, the most prevalent type of dementia was unspecified dementia (56%), followed by AD (31%), VD (12%), PDD (10%), DLB (3%), and FTD (&lt;\u20091%), and most patients had scores indicating severe illness on the Charlson Comorbidity Index (71%) and frailty index (62%). Across all dementia types, IRs (per 100 person-years) were high for emergency department visits, oral anti-infective use, and urinary tract infections after the initial psychosis diagnosis. Patients with DLB had the highest incidence of most clinical outcomes. After 1\u00a0year of follow-up, the cumulative probability of death was about 30% for all dementia types, and after 5\u00a0years, was about 80% among patients with DLB, VD, AD, or PDD and about 60%-65% among patients with FTD or unspecified dementia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with dementia-related psychosis had a high burden of comorbidities, frailty, emergency department visits, infections, and death. Specifically, after DRP diagnosis, patients with DLB and VD had the highest burden of clinical events of interest.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12877-022-03489-3","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T17:05:06Z","timestamp":1665075906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical outcomes and treatment patterns of older adults with dementia-related psychosis by dementia type in the United States"],"prefix":"10.1186","volume":"22","author":[{"given":"Joan","family":"Forns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather E.","family":"Danysh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa J.","family":"McQuay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ellen","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary S.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Demos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Bradley","family":"Layton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"3489_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fneur.2012.00073","volume":"3","author":"J Cerejeira","year":"2012","unstructured":"Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.","journal-title":"Front Neurol"},{"issue":"9","key":"3489_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1017\/S1041610212000609","volume":"24","author":"ST Cheng","year":"2012","unstructured":"Cheng ST, Kwok T, Lam LC. Neuropsychiatric symptom clusters of Alzheimer\u2019s disease in Hong Kong Chinese: prevalence and confirmatory factor analysis of the Neuropsychiatric Inventory. Int Psychogeriatr. 2012;24(9):1465\u201373.","journal-title":"Int Psychogeriatr"},{"issue":"10","key":"3489_CR3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.biopsych.2015.03.028","volume":"78","author":"D Galimberti","year":"2015","unstructured":"Galimberti D, Dell\u2019Osso B, Altamura AC, Scarpini E. Psychiatric symptoms in frontotemporal dementia: epidemiology, phenotypes, and differential diagnosis. Biol Psychiatry. 2015;78(10):684\u201392.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"3489_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.psc.2011.02.008","volume":"34","author":"A Iglewicz","year":"2011","unstructured":"Iglewicz A, Meeks TW, Jeste DV. New wine in old bottle: late-life psychosis. Psychiatr Clin North Am. 2011;34(2):295\u2013318, vii.","journal-title":"Psychiatr Clin North Am"},{"issue":"3","key":"3489_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40263-020-00707-7","volume":"34","author":"M Marcinkowska","year":"2020","unstructured":"Marcinkowska M, Sniecikowska J, Fajkis N, Pasko P, Franczyk W, Kolaczkowski M. Management of dementia-related psychosis, agitation and aggression: a review of the pharmacology and clinical effects of potential drug candidates. CNS Drugs. 2020;34(3):243\u201368.","journal-title":"CNS Drugs"},{"issue":"2","key":"3489_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11920-014-0542-0","volume":"17","author":"MM Reinhardt","year":"2015","unstructured":"Reinhardt MM, Cohen CI. Late-life psychosis: diagnosis and treatment. Curr Psychiatry Rep. 2015;17(2):1.","journal-title":"Curr Psychiatry Rep"},{"issue":"12","key":"3489_CR7","doi-asserted-by":"publisher","first-page":"e1620","DOI":"10.1212\/WNL.0000000000011632","volume":"96","author":"JB Wetmore","year":"2021","unstructured":"Wetmore JB, Peng Y, Yan H, et al. Association of dementia-related psychosis with long-term care use and death. Neurology. 2021;96(12):e1620\u201331.","journal-title":"Neurology"},{"key":"3489_CR8","unstructured":"Pimavanserin Prescribing Information. Acadia Pharmaceuticals Inc. NUPLAZID (pimavanserin). April 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/207318lbl.pdf. Accessed 11 Mar 2022."},{"key":"3489_CR9","unstructured":"FDA. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. US Food and Drug Administration; April 11, 2005. https:\/\/wayback.archive-it.org\/7993\/20170113112252\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm053171.htm. Accessed 1 Sept 2022."},{"issue":"15","key":"3489_CR10","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934\u201343.","journal-title":"JAMA"},{"issue":"1","key":"3489_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/archinternmed.2009.456","volume":"170","author":"ER Dorsey","year":"2010","unstructured":"Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96\u2013103.","journal-title":"Arch Intern Med"},{"issue":"3","key":"3489_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamainternmed.2014.6930","volume":"175","author":"LA Fraser","year":"2015","unstructured":"Fraser LA, Liu K, Naylor KL, et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. JAMA Intern Med. 2015;175(3):450\u20132.","journal-title":"JAMA Intern Med"},{"key":"3489_CR13","first-page":"1363","volume":"9","author":"P Gareri","year":"2014","unstructured":"Gareri P, Segura-Garcia C, Manfredi VG, et al. Use of atypical antipsychotics in the elderly: a clinical review. Clin Interv Aging. 2014;9:1363\u201373.","journal-title":"Clin Interv Aging"},{"issue":"7","key":"3489_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.7326\/0003-4819-152-7-201004060-00006","volume":"152","author":"G Trifiro","year":"2010","unstructured":"Trifiro G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med. 2010;152(7):418\u201325 W139-40.","journal-title":"Ann Intern Med"},{"issue":"3","key":"3489_CR15","doi-asserted-by":"publisher","first-page":"e190828","DOI":"10.1001\/jamanetworkopen.2019.0828","volume":"2","author":"I Yunusa","year":"2019","unstructured":"Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis. JAMA Netw Open. 2019;2(3):e190828.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"3489_CR16","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2019","unstructured":"American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674\u201394.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"3489_CR17","first-page":"367","volume":"27","author":"M Frazer","year":"2021","unstructured":"Frazer M, Abler V, Halpern R, Skoog B, Rashid N. Burden of illness among patients with dementia-related psychosis. J Manag Care Spec Pharm. 2021;27(3):367\u201378.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"3489_CR18","first-page":"e109","volume":"18","author":"DL Leslie","year":"2012","unstructured":"Leslie DL, Rosenheck R. Off-label use of antipsychotic medications in Medicaid. Am J Manag Care. 2012;18(3):e109\u201317.","journal-title":"Am J Manag Care"},{"issue":"6","key":"3489_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3928\/19404921-20160920-03","volume":"9","author":"WE Mansbach","year":"2016","unstructured":"Mansbach WE, Mace RA, Clark KM, Firth IM, Breeden JK. Predicting off-label antipsychotic medication use in a randomly selected nursing home sample based on resident and facility characteristics. Res Gerontol Nurs. 2016;9(6):257\u201366.","journal-title":"Res Gerontol Nurs"},{"issue":"8","key":"3489_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/jpm.12488","volume":"25","author":"LJ Phillips","year":"2018","unstructured":"Phillips LJ, Birtley NM, Petroski GF, Siem C, Rantz M. An observational study of antipsychotic medication use among long-stay nursing home residents without qualifying diagnoses. J Psychiatr Ment Health Nurs. 2018;25(8):463\u201374.","journal-title":"J Psychiatr Ment Health Nurs"},{"issue":"4","key":"3489_CR21","first-page":"188","volume":"12","author":"WP Glasheen","year":"2019","unstructured":"Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12(4):188\u201397.","journal-title":"Am Health Drug Benefits"},{"issue":"4","key":"3489_CR22","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/EDE.0000000000000833","volume":"29","author":"CC Cuthbertson","year":"2018","unstructured":"Cuthbertson CC, Kucharska-Newton A, Faurot KR, et al. Controlling for frailty in pharmacoepidemiologic studies of older adults: validation of an existing Medicare claims\u2013based algorithm. Epidemiology. 2018;29(4):556\u201361.","journal-title":"Epidemiology"},{"issue":"1","key":"3489_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/pds.3719","volume":"24","author":"KR Faurot","year":"2015","unstructured":"Faurot KR, Jonsson Funk M, Pate V, et al. Using claims data to predict dependency in activities of daily living as a proxy for frailty. Pharmacoepidemiol Drug Saf. 2015;24(1):59\u201366.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"3489_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/sim.4780100317","volume":"10","author":"AJ Dobson","year":"1991","unstructured":"Dobson AJ, Kuulasmaa K, Eberle E, Scherer J. Confidence intervals for weighted sums of Poisson parameters. Stat Med. 1991;10(3):457\u201362.","journal-title":"Stat Med"},{"issue":"7","key":"3489_CR25","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/aje\/kwu289","volume":"181","author":"H Dong","year":"2015","unstructured":"Dong H, Robison LL, Leisenring WM, Martin LJ, Armstrong GT, Yasui Y. Estimating the burden of recurrent events in the presence of competing risks: the method of mean cumulative count. Am J Epidemiol. 2015;181(7):532\u201340.","journal-title":"Am J Epidemiol"},{"key":"3489_CR26","unstructured":"Thomas S, Chirila C, Ritchey MB. Visualization of patient electronic records to support exploratory analysis and variable derivation of categorical data. Paper RIV-66 - Presented at the 25th Annual SouthEast SAS Users Group (SESUG). Cary. 2017. https:\/\/sesug.org\/SESUG2017\/DocPDF\/SESUG_2017_Academic_Paper_Summmary_for_Website.pdf."},{"issue":"1","key":"3489_CR27","first-page":"81","volume":"15","author":"VI Reus","year":"2017","unstructured":"Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Focus (Am Psychiatr Publ). 2017;15(1):81\u20134.","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"12","key":"3489_CR28","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/gerona\/glz045","volume":"74","author":"RE Kheirbek","year":"2019","unstructured":"Kheirbek RE, Fokar A, Little JT, et al. Association between antipsychotics and all-cause mortality among community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2019;74(12):1916\u201321.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"3489_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10654-020-00643-2","volume":"36","author":"C Mueller","year":"2021","unstructured":"Mueller C, John C, Perera G, Aarsland D, Ballard C, Stewart R. Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. Eur J Epidemiol. 2021;36(1):89\u2013101.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"3489_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/0706743716673321","volume":"62","author":"J Kirkham","year":"2017","unstructured":"Kirkham J, Sherman C, Velkers C, et al. Antipsychotic use in dementia. Can J Psychiatry. 2017;62(3):170\u201381.","journal-title":"Can J Psychiatry"},{"issue":"1","key":"3489_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jalz.2016.04.002","volume":"13","author":"RA Goodman","year":"2017","unstructured":"Goodman RA, Lochner KA, Thambisetty M, Wingo TS, Posner SF, Ling SM. Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011\u20132013. Alzheimers Dement. 2017;13(1):28\u201337.","journal-title":"Alzheimers Dement"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-022-03489-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-022-03489-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-022-03489-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T17:06:14Z","timestamp":1665075974000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-022-03489-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3489"],"URL":"https:\/\/doi.org\/10.1186\/s12877-022-03489-3","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"3 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Triangle Institute (RTI) International Institutional Review Board (IRB) reviewed the study protocol (Study ID 21086) and determined that this study met the criteria for exemption from IRB review. The RTI International IRB granted a waiver from requiring written informed consent. The study protocol was also reviewed by the Centers for Medicare and Medicaid Services\u2019 (CMS) Privacy Board, which approved the use of the Medicare Research Identifiable Files (including the master beneficiary summary base file, MedPAR file, outpatient file, carrier [professional\/physician] file, part D drug event file, durable medical equipment file, home health agency file) for use in this study under a data use agreement with RTI Health Solutions (DUA RSCH-2020\u201355942). The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MET and CD are employees of Acadia Pharmaceuticals, which produces an antipsychotic treatment. GD was an employee of Acadia Pharmaceuticals at the time this work was conducted. JF, HED, LJM, MSA and JBL are employees of RTI Health Solutions. This study was conducted by RTI Health Solutions with funding from Acadia Pharmaceuticals under a contract that included independent publication rights.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"784"}}